The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Prednisone Might be the Missing Ingredient in the American College of Rheumatology’s Recommendations for Treating Patients with Rheumatoid Arthritis

Prednisone Might be the Missing Ingredient in the American College of Rheumatology’s Recommendations for Treating Patients with Rheumatoid Arthritis

April 1, 2013 • By John Kirwan, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF
What About Prednisone?


Editor’s note: The ACR recently released a call for possible partners for a new RA guideline development effort beginning this year. The new guidelines would include DMARDs, steroids, and biologics, including newer oral agents. Look for more information on these efforts in the May issue of The Rheumatologist.

You Might Also Like
  • Why Oral Corticosteroids Should Not be Used in Patients with Rheumatoid Arthritis
  • Is Predisone 3 mg/day an Appropriate Dose for Patients with Rheumatoid Arthritis?
  • 2014 ACR/ARHP Annual Meeting: Rheumatoid Arthritis Management Treatment Recommendations
Explore This Issue
April 2013
Also By This Author
  • Patients Add Power to Research Initiatives

Enthusiasm for the new often results in overlooking the continuing, or even developing, advantages of the familiar. Thus, in our enthusiasm to embrace new treatment options, we may fail to notice that existing therapies, used in appropriate ways, offer more than we first thought.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The pharmaceutical industry is locked into a commercial system that demands the development and promotion of new agents to maintain patent rights and continuing income generation, and has no interest in the intelligent use of existing agents. Rheumatologists, on the other hand, are looking for the best treatment options independently of commercial considerations. Remember the story of methotrexate? In the 1950s, it was used in anticancer therapy and in patients with severe psoriasis. It was noticed that, in some patients, their psoriatic arthritis improved, and in a landmark paper from the Royal National Hospital for Rheumatic Diseases in Bath, Kersley reported the first series of 10 patients successfully treated for psoriatic arthritis.1 It was not long before methotrexate was taken up for rheumatoid arthritis (RA) as well, and in a series of substantial and important randomized controlled trials, led principally from North America, the rheumatology community established its clear success as a disease-modifying agent.

Historical Look at Glucocorticoids

Finding the best way to use glucocorticoids in the treatment of RA is another example of clinical persistence in the face of commercial neglect. In their seminal report announcing the therapeutic use of glucocorticoids for the first time, Hench, Kendall, Slocumb, and Polley recalled that it was 1929 when Hench first noted the beneficial effects of pregnancy and jaundice on RA.2 It was this observation that started the hunt for an underlying agent, but it was not until 1948 that a sufficient amount was available to test it in a patient with RA. The symptomatic benefit was astounding.2,3

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The efficacy of glucocorticoids in treating inflammation was established early, but enthusiastic overtreatment also led to some early serious adverse effects and the pharmaceutical industry turned to the development of nonsteroidal antiinflammatory drugs. While glucocorticoids are widely used, particularly in the U.S., their use was, paradoxically, widely condemned.4

Pages: 1 2 3 | Single Page

Filed Under: Conditions, DMARDs & Immunosuppressives, Drug Updates, Rheumatoid Arthritis Tagged With: AC&R, Glucocorticoids, prednisone, RA, Rheumatoid arthritis, SteroidIssue: April 2013

You Might Also Like:
  • Why Oral Corticosteroids Should Not be Used in Patients with Rheumatoid Arthritis
  • Is Predisone 3 mg/day an Appropriate Dose for Patients with Rheumatoid Arthritis?
  • 2014 ACR/ARHP Annual Meeting: Rheumatoid Arthritis Management Treatment Recommendations
  • Pharmaceutical Care Models, Tools for Treating Patients with Rheumatoid Arthritis

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)